BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
- angiotensin-converting enzyme (ACE)
- mRNA vaccine
FingerprintDive into the research topics of 'A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review'. Together they form a unique fingerprint.
Recent Findings from Tohoku University Provides New Insights into COVID-19 (A Novel Development of Sarcoidosis Following Covid-19 Vaccination and a Literature Review)
1 item of Media coverage